Precigen (PGEN) Stock Price, News & Analysis

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PGEN, but not buy additional shares or sell existing shares.
View PGEN analyst ratings or view top-rated stocks.

3 brokerages have issued 1 year price targets for Precigen's stock. Their PGEN share price targets range from $6.00 to $14.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 651.9% from the stock's current price.
View analysts price targets for PGEN or view top-rated stocks among Wall Street analysts.

Precigen's stock was trading at $1.34 at the beginning of 2024. Since then, PGEN shares have decreased by 0.7% and is now trading at $1.33.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PGEN earnings forecast.

Precigen, Inc. (NASDAQ:PGEN) posted its quarterly earnings results on Tuesday, March, 19th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biotechnology company had revenue of $1.23 million for the quarter, compared to the consensus estimate of $2.03 million. Precigen had a negative net margin of 1,540.63% and a negative trailing twelve-month return on equity of 55.47%.

Virtus LifeSci Biotech Clinical Trials ETF holds 68,764 shares of PGEN stock, representing 0.91% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC).

Precigen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (0.28%) and LexAurum Advisors LLC (0.04%). Insiders that own company stock include David M Obstler, Dean J Mitchell, Donald P Lehr, Harry Jr Thomasian, Helen Sabzevari, Jeffrey B Kindler, Jeffrey Thomas Perez, Jennifer I Ansberry, John N Digiacomo, Randal J Kirk, Rutul R Shah, Steven Frank and Trading SA Ares.
View institutional ownership trends.

Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.